Literature DB >> 25211373

Oridonin's therapeutic effect: suppressing Th1/Th17 simultaneously in a mouse model of Crohn's disease.

Shubei Wang1, Yong Zhang, Philippe Saas, Haili Wang, Ying Xu, Ke Chen, Jie Zhong, Yaozong Yuan, Ying Wang, Yunwei Sun.   

Abstract

BACKGROUND AND AIM: Crohn's disease is a chronic inflammatory bowel disease. Oridonin is an effective component isolated from Rabdosia rubescens. It can inhibit the activation of transcription factor nuclear factor-kappa B and suppress the over expression of cytokines. We postulated that oridonin may be a potential therapeutic candidate for Crohn's disease.
METHODS: To confirm the postulation, we investigated clinical and immunologic modulations of oridonin in a mouse model of trinitrobenzene sulfonic acid-induced colitis.
RESULTS: It was found that oridonin attenuated trinitrobenzene sulfonic acid-induced colitis as represented by a reduction in colonic interferon-γ/inteleukin-17 secretion and a decrement in splenic Th1/Th17 cells and effector memory CD4(+) T cells. Oridonin treatment inhibited the proliferation of CD4(+) T cells and upregulated the apoptosis of lymphocytes by inhibiting nuclear translocation of transcription factor nuclear factor-kappa B.
CONCLUSIONS: Oridonin is a potential modulator for trinitrobenzene sulfonic acid-induced colitis and other Th1/Th17 mediated inflammatory diseases.
© 2014 Journal of Gastroenterology and Hepatology Foundation and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  animal models; cytokines; oridonin

Mesh:

Substances:

Year:  2015        PMID: 25211373     DOI: 10.1111/jgh.12710

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  16 in total

Review 1.  Therapeutic implications of inflammasome in inflammatory bowel disease.

Authors:  Vishal Khatri; Ramaswamy Kalyanasundaram
Journal:  FASEB J       Date:  2021-05       Impact factor: 5.834

Review 2.  Molecular Insight in the Multifunctional Effects of Oridonin.

Authors:  Brice Ayissi Owona; Herman J Schluesener
Journal:  Drugs R D       Date:  2015-09

3.  Sodium selenite ameliorates dextran sulfate sodium-induced chronic colitis in mice by decreasing Th1, Th17, and γδT and increasing CD4(+)CD25(+) regulatory T-cell responses.

Authors:  Li-Xuan Sang; Bing Chang; Jun-Feng Zhu; Fang-Li Yang; Yan Li; Xue-Feng Jiang; Da-Nan Wang; Chang-Long Lu; Xun Sun
Journal:  World J Gastroenterol       Date:  2017-06-07       Impact factor: 5.742

4.  Suppression of Th17 Cell Response in the Alleviation of Dextran Sulfate Sodium-Induced Colitis by Ganoderma lucidum Polysaccharides.

Authors:  Bing Wei; Ran Zhang; Jingbo Zhai; Junfeng Zhu; Fangli Yang; Dan Yue; Xiaoyi Liu; Changlong Lu; Xun Sun
Journal:  J Immunol Res       Date:  2018-05-20       Impact factor: 4.818

5.  Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity.

Authors:  Hongbin He; Hua Jiang; Yun Chen; Jin Ye; Aoli Wang; Chao Wang; Qingsong Liu; Gaolin Liang; Xianming Deng; Wei Jiang; Rongbin Zhou
Journal:  Nat Commun       Date:  2018-06-29       Impact factor: 14.919

Review 6.  Catechins and Their Therapeutic Benefits to Inflammatory Bowel Disease.

Authors:  Fei-Yan Fan; Li-Xuan Sang; Min Jiang
Journal:  Molecules       Date:  2017-03-19       Impact factor: 4.411

Review 7.  Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors.

Authors:  Yang Yang; Huanan Wang; Mohammed Kouadir; Houhui Song; Fushan Shi
Journal:  Cell Death Dis       Date:  2019-02-12       Impact factor: 8.469

Review 8.  Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance.

Authors:  Xi Liu; Jimin Xu; Jia Zhou; Qiang Shen
Journal:  Genes Dis       Date:  2020-07-05

Review 9.  Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection.

Authors:  Jimin Xu; Eric A Wold; Ye Ding; Qiang Shen; Jia Zhou
Journal:  Molecules       Date:  2018-02-22       Impact factor: 4.411

Review 10.  Pharmacological Inhibitors of the NLRP3 Inflammasome.

Authors:  Ayesha Zahid; Bofeng Li; Arnaud John Kombe Kombe; Tengchuan Jin; Jinhui Tao
Journal:  Front Immunol       Date:  2019-10-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.